A comparison of overall survival with brexucabtagene autoleucel (Brexu-cel) CAR T-cell therapy (ZUMA-2) and standard of care (SCHOLAR-2) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) previously treated with a covalent bruton tyrosine kinase inhibitor (BTKi)
Hess, G. Dreyling, M. Oberic, L. Gine, E. Zinzani, P. L. Vilmar, A. Jerkeman, M. Chen, J. M. H. Ohler, A.
Hess, G.
Dreyling, M.
Oberic, L.
Gine, E.
Zinzani, P. L.
Vilmar, A.
Jerkeman, M.
Chen, J. M. H.
Ohler, A.
Citations
Altmetric:
Abstract
Authors
Hess, G.
Dreyling, M.
Oberic, L.
Gine, E.
Zinzani, P. L.
Linton, Kim M
Vilmar, A.
Jerkeman, M.
Chen, J. M. H.
Ohler, A.
Stilgenbauer, S.
Thieblemont, C.
Lambert, J.
Zilioli, V. R.
Sancho, J. M.
Jimenez-Ubieto, A.
Fischer, L.
Eyre, T. A.
Keeping, S.
Park, J. E.
Wu, J. J.
Siddiqi, R.
Reitan, J.
Castaigne, G.
Salles, G.
Dreyling, M.
Oberic, L.
Gine, E.
Zinzani, P. L.
Linton, Kim M
Vilmar, A.
Jerkeman, M.
Chen, J. M. H.
Ohler, A.
Stilgenbauer, S.
Thieblemont, C.
Lambert, J.
Zilioli, V. R.
Sancho, J. M.
Jimenez-Ubieto, A.
Fischer, L.
Eyre, T. A.
Keeping, S.
Park, J. E.
Wu, J. J.
Siddiqi, R.
Reitan, J.
Castaigne, G.
Salles, G.
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton KM, et al. A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi). Blood. 2022 Nov;140:10296-9. PubMed PMID: WOS:000893230303139.